Mepact may improve your patients’ chance of a future with a significant increase in overall survival of 8%* 1

*compared with chemotherapy alone

In combination with chemotherapy, compared with chemotherapy alone:1

  • Mepact increases patients’ six-year overall survival rates from 70–78% (p=0.03)
  • Mepact decreases the relative risk of death by 29% (hazard ratio 0.71, 95% CI: 0.52-0.96)

OVERALL SURVIVAL

Close

OVERALL SURVIVAL

Adding Mepact to chemotherapy was associated with improved event-free survival1

At 6 years follow-up, event-free survival with Mepact in combination with chemotherapy was 67% vs. 61% for chemotherapy alone (p=0.08)1

Event-free survival with Mepact demonstrated a similar trend to the co-primary endpoint overall survival1 – considered the ‘gold standard’ endpoint for cancer drug clinical trials2

It is recognised by the EMA that surrogate endpoints, such as event-free survival, may not be consistent with overall survival when evaluating immunomodulators. This may be due to the mode of action, where it takes time for changes to the immune system to take effect3

EVENT-FREE SURVIVAL

Close

EVENT-FREE SURVIVAL